Many health and wellness stocks have faced challenges in recent years as GLP-1 weight-loss drugs like Ozempic and Wegovy upend the traditional diet market. Companies that once dominated the space have struggled to keep up with this new wave of solutions.
Among them, WW International (WW), formerly known as WeightWatchers, hit a rough patch earlier this year, resulting in WW filing for bankruptcy protections. But now, the company has made a comeback, completing its financial restructuring and relisting its stock on the Nasdaq Exchange.
As part of this return, WeightWatchers is repositioning itself entirely. The company is pivoting toward women’s health, launching a new menopause-focused program while also deepening ties with GLP-1 drug developers like Novo Nordisk (NVO).
For investors wondering whether this turnaround could be more than a short-term pop, now may be the right time to take a closer look at WW’s evolving story.
About WW Stock
Based in New York, WW International is a global wellness company offering digital health and fitness solutions, personalized nutrition guidance, subscription-based weight management services, and coaching. WW leverages its proprietary app, community support, and innovative programs to empower members worldwide to adopt healthier lifestyles and sustainable habits.
WW’s exit from Chapter 11 which slashed $1.15 billion in debt and saw it relist on the Nasdaq Exchange at $27. Shares are up more than 16% over the past five days.
Catalysts to Watch
WW’s core growth driver is a new women’s health program targeting perimenopause and menopause, set to roll out later this year. The initiative will combine tailored nutrition plans, behavioral coaching, hormone replacement therapy, and dedicated community groups for women aged 40–60. With up to 70% of women experiencing weight gain during menopause, WW sees a data‑backed need for this service.
Rather than abandoning GLP‑1 therapies, the company will integrate these medications, such as Wegovy, into its model, pairing drug support with coaching to mitigate side effects and enhance results. A recent partnership with Novo Nordisk’s NovoCare pharmacy ensures members receive FDA‑approved prescriptions within WW’s supervised framework. CMO Dr. Kim Boyd says this blended approach of medication, lifestyle change, and community “fills a critical gap in women’s healthcare.”
WeightWatchers Posts Mixed Q1 Earnings
While the company is still working through its restructuring, some signs of stabilization are starting to appear.
Revenue for the first quarter came in at $186.6 million, which was down nearly 10% from the same period last year. Most of that decline came from its traditional “Behavioral” business that includes digital memberships and in-person workshops.
The total subscriber count dropped to about 3.4 million, a 14% year-over-year decrease. However, not all segments were weak. The “Clinical” business, its telehealth offering, actually grew, with paying members in that category rising 55% to 135,000. That jump helped clinical revenue grow about 57% over the past year.
On the profit side, the company showed improvement. WW posted a net loss of $72.6 million, which is still sizable, but far better than the $347.9 million loss in the year-ago quarter. Management has been cutting costs aggressively, and it’s starting to show.
Investors should note that Q1 results were released on May 6, the same day the company filed for bankruptcy protections.
Analyst Opinions and Final Words
Wall Street analysts have rated the stock a “Hold.” Their average 12-month price target of $0.94 is significantly lower than its current share price, but investors should note that analysts likely have not caught up to shares following the bankruptcy exit. This means WW could quickly see refreshed targets.
It is good news that WW has emerged from bankruptcy, but a sustained turnaround will take time to play out. Investors will want to see steady membership and growth in its new health services before calling it a success.
